Results 11 to 20 of about 201 (100)

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients

CPT: Pharmacometrics & Systems Pharmacology, 2021
Letermovir is indicated for prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Two‐stage population pharmacokinetic (PK) modeling of letermovir was conducted to support dose rationale ...
Marita Prohn, Anders Viberg, Da Zhang, Kevin Dykstra, Casey Davis, Sreeraj Macha, Philip Sabato, Dinesh deAlwis, Marian Iwamoto, Craig Fancourt, Carolyn R. Cho   +10 more
doaj   +1 more source

Enantioselective aza-Michael Cyclization Reaction Catalyzed by Quinine-Derived Monoquaternary Ammonium Salts: an Effective Route to Synthesize Letermovir

Pharmaceutical Fronts, 2021
A series of mono- or bis-quaternary ammonium salts derived from cinchonidine or quinine was synthesized and screened as potent phase-transfer catalysts for the reaction of aza-Michael cyclization, the key step in the synthesis of letermovir.
Liang Chen, Wei-Yuan Liu, Si-Ju Bi, Ting Zhou, Jing Pan, Xun-Lei Lv, Kuai-Le Lin, Wei-Cheng Zhou   +7 more
doaj   +1 more source

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients

Immunity, Inflammation and Disease, 2021
Letermovir prophylaxis in allogeneic hematopoietic cell transplant recipients significantly reduces the incidence of clinically significant cytomegalovirus infection. However, breakthrough infections still occur despite adequate prophylaxis.
Léna Royston, Eva Royston, Stavroula Masouridi‐Levrat, Yves Chalandon, Christian Van Delden, Dionysios Neofytos   +5 more
doaj   +1 more source

Letermovir Prophylaxis for Cytomegalovirus [PDF]

New England Journal of Medicine, 2018
Marty and colleagues (Dec. 21 issue)1 found that letermovir prophylaxis after hematopoietic-cell transplantation resulted in a lower risk of clinically significant cytomegalovirus (CMV) infection than placebo. This trial shows that a prophylactic agent can provide meaningful benefit after hematopoietic-cell transplantation, without considerable ...
Francisco M, Marty, Johan, Maertens, Cyrus, Badshah   +2 more
openaire   +6 more sources

Letermovir salvage therapy in the management of a case of cytomegalovirus ventriculitis complicated by drug resistance

Clinical Infection in Practice, 2020
Reported is a case of cytomegalovirus ventriculitis on a background of HIV infection. Sequencing demonstrated viral mutations conferring resistance to available therapies.
Andrew Bosworth, Sowsan F. Atabani, Anastasia Theodosiou, Avneet Shahi, Tatiana Peate, Steven Wilson, Emanuela Pelosi, Andrew Rosser   +7 more
doaj   +1 more source

Antiviral therapy defiant mixed viral retinitis post hematopoietic allogeneic stem cell transplant

Clinical Case Reports, 2023
Cytomegalovirus (CMV) retinitis is an uncommon presentation post allogeneic transplant and can be vision‐threatening. Our case demonstrates the occurrence of polymerase chain reaction (PCR) proven mixed viral retinitis (cytomegalovirus and varicella ...
Nadia Gabarin, Rohan Dadak, Mili Roy, Alexander J. Kaplan, Shariq Haider, Dina Khalaf   +5 more
doaj   +1 more source

Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study

BMJ Open, 2023
Introduction Chronic cytomegalovirus (CMV) infection is very frequent in people living with HIV (PLWH). High anti-CMV IgG titres, which may be linked to transient CMV replication, have been associated with earlier mortality, CD8 T-cell expansion, lower ...
Jean-Pierre Routy, Bertrand Lebouché, Nicolas Chomont, Stéphane Isnard, Réjean Thomas, Talat Bessissow, Guy Boivin, Alexandra de Pokomandy, Nadine Kronfli, Marina Klein, Cécile Tremblay, Léna Royston, Simeng Bu, Carolina A. Berini, Peter L. Lakatos, Cecilia T. Costiniuk   +15 more
doaj   +1 more source

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients

Microbiology Spectrum, 2022
De novo mutations in the UL56 terminase subunit and its associated phenotypes were studied in the context of cytomegalovirus (CMV) transplant recipients clinically resistant to DNA-polymerase inhibitors, naive to letermovir.
Marta Santos Bravo, Valentin Tilloy, Nicolas Plault, Sonsoles Sánchez Palomino, María Mar Mosquera, Mireia Navarro Gabriel, Francesc Fernández Avilés, María Suárez Lledó, Montserrat Rovira, Asunción Moreno, Laura Linares, Marta Bodro, Sébastien Hantz, Sophie Alain, María Ángeles Marcos   +14 more
doaj   +1 more source

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient

European Journal of Case Reports in Internal Medicine, 2020
Infection with cytomegalovirus (CMV) with resistance to ganciclovir (GCV) is a therapeutic challenge in kidney transplant patients, because standard treatment options are nephrotoxic. We report the case of a kidney transplant recipient with GCV-resistant
Uta Köpf, Hans Ulrich Klehr, Anna-Maria Eis-Huebinger, Souhaib Aldabbagh, Christian Strassburg, Dominik Boes, Philipp Lutz   +6 more
doaj   +1 more source

Real-world use of letermovir for CMV prevention in allogeneic hematopoietic cell transplantation recipients in France: a national claims database study

Frontiers in Virology
BackgroundLetermovir is the only drug indicated for the prophylaxis of cytomegalovirus (CMV) reactivation in CMV-positive allogeneic hematopoietic cell transplantation (HCT) recipients.
Sophie Ducastelle-Lepretre, Isabelle Durand-Zaleski, Marion Apert, Claire Castagné, Xavier Bourge, Guilhem Tournaire, Stève Bénard, Louis Chillotti, Françoise Bugnard, Charlotte Cancalon, Régis Peffault de Latour   +10 more
doaj   +1 more source